Expression of the adhesion molecules CD49d and CD49e on G-CSF-mobilized CD34+ cells of patients with solid tumors or non-Hodgkin's and Hodgkin's lymphoma and of healthy donors is inversely correlated with the amount of mobilized CD34+ cells.
The yield of CD34+ PBPC and colony-forming units-granulocyte-macrophage (CFU-GM) in leukapheresis products and the expression of the adhesion molecules CD11a, CD31, CD49d, CD49e, CD54, CD58, CD62L, c-kit (CD117), Thy-1 (CD90), CD33, CD38, and HLA-DR on CD34+ PBPC were analyzed in patients with cancer of the testis (n = 10), breast cancer (n = 10), Hodgkin's disease (n = 20), high-grade (n = 20) and low-grade (n = 20) non-Hodgkin's lymphoma, and healthy donors (n = 20) undergoing G-CSF (filgrastim)-stimulated PBPC mobilization. For each disease entity, G-CSF was administered in two different doses, 10 microg G-CSF/kg body weight (BW)/day s.c. vs. 24 microg G-CSF/kg BW s.c./day in steady-state condition. Data were compared for each dose group separately. Patients with cancer of the testis and breast cancer mobilized significantly more CD34+ cells than patients with high-grade and low-grade non-Hodgkin's lymphoma and Hodgkin's disease (p<0.05). Correspondingly, expression of CD49d on CD34+ PBPC was significantly lower in the same patients with cancer of the testis compared with high-grade and low-grade non-Hodgkin's lymphoma and Hodgkins' disease and in patients with breast cancer compared with high-grade and low-grade non-Hodgkin's lymphoma, Hodgkins's disease, and healthy donors. Similar results were obtained for CD49e. These data suggest that the expression of the adhesion molecules CD49d and CD49e on G-CSF-mobilized CD34+ cells of patients with solid tumors, non-Hodgkin's lymphoma, Hodgkin's disease, and healthy donors is inversely correlated with the amount of mobilized CD34+ cells.
Zeller
W
W
Department Oncology and Hematology, and Institute of Mathematics and Computer Science in Medicine, University Hospital Hamburg, Germany.
Kröger
N
N
Berger
J
J
Krueger
W
W
Dierlamm
J
J
Stockschläder
M
M
Gutensohn
K
K
Hossfeld
D K
DK
Zander
A R
AR
D000293:Adolescent; D000328:Adult; D015703:Antigens, CD / Q000032:analysis; D018952:Antigens, CD34 / Q000032:analysis; D001943:Breast Neoplasms / Q000276:immunology / Q000473:pathology* / Q000628:therapy; D015815:Cell Adhesion Molecules / Q000032:analysis*; D003114:Colony-Forming Units Assay; D005260:Female; D000069585:Filgrastim; D016179:Granulocyte Colony-Stimulating Factor / Q000494:pharmacology / Q000627:therapeutic use*; D019650:Hematopoietic Stem Cell Mobilization / Q000379:methods*; D006412:Hematopoietic Stem Cells / Q000166:cytology / Q000276:immunology* / Q000473:pathology; D006689:Hodgkin Disease / Q000276:immunology / Q000473:pathology* / Q000628:therapy; D006801:Humans; D039441:Integrin alpha4; D039482:Integrin alpha5; D016023:Integrins / Q000032:analysis; D008228:Lymphoma, Non-Hodgkin / Q000276:immunology / Q000473:pathology* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins; D012016:Reference Values; D013736:Testicular Neoplasms / Q000276:immunology / Q000473:pathology* / Q000628:therapy
D015703:Antigens, CD; D018952:Antigens, CD34; D015815:Cell Adhesion Molecules; D039482:Integrin alpha5; D016023:Integrins; D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; D039441:Integrin alpha4; D000069585:Filgrastim